Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Literature DB >> 31575532

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Alfred L Garfall¹, Ehren K Dancy², Adam D Cohen¹, Wei-Ting Hwang³, Joseph A Fraietta^4,5,6, Megan M Davis^5,6, Bruce L Levine^5,6, Don L Siegel^5,6, Edward A Stadtmauer¹, Dan T Vogl¹, Adam Waxman¹, Aaron P Rapoport⁷, Michael C Milone^5,6, Carl H June^5,6, J Joseph Melenhorst^5,6.

Abstract

Entities: Disease Gene

Year: 2019 PMID： 31575532 PMCID： PMC6784521 DOI： 10.1182/bloodadvances.2019000600

Source DB: PubMed Journal: Blood Adv ISSN： 2473-9529

× No keyword cloud information.

11 in total

1. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Authors: Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Hong-Bin Fang; Ling Cai; Stephen Janofsky; Anne Chew; Jan Storek; Gorgun Akpek; Ashraf Badros; Saul Yanovich; Ming T Tan; Elizabeth Veloso; Marcela F Pasetti; Alan Cross; Sunita Philip; Heather Murphy; Rita Bhagat; Zhaohui Zheng; Todd Milliron; Julio Cotte; Andrea Cannon; Bruce L Levine; Robert H Vonderheide; Carl H June
Journal: Blood Date: 2010-10-28 Impact factor: 22.113

2. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Authors: Noopur Raje; Jesus Berdeja; Yi Lin; David Siegel; Sundar Jagannath; Deepu Madduri; Michaela Liedtke; Jacalyn Rosenblatt; Marcela V Maus; Ashley Turka; Lyh-Ping Lam; Richard A Morgan; Kevin Friedman; Monica Massaro; Julie Wang; Greg Russotti; Zhihong Yang; Timothy Campbell; Kristen Hege; Fabio Petrocca; M Travis Quigley; Nikhil Munshi; James N Kochenderfer
Journal: N Engl J Med Date: 2019-05-02 Impact factor: 91.245

3. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

Authors: Adam D Cohen; Alfred L Garfall; Edward A Stadtmauer; J Joseph Melenhorst; Simon F Lacey; Eric Lancaster; Dan T Vogl; Brendan M Weiss; Karen Dengel; Annemarie Nelson; Gabriela Plesa; Fang Chen; Megan M Davis; Wei-Ting Hwang; Regina M Young; Jennifer L Brogdon; Randi Isaacs; Iulian Pruteanu-Malinici; Don L Siegel; Bruce L Levine; Carl H June; Michael C Milone
Journal: J Clin Invest Date: 2019-03-21 Impact factor: 14.808

4. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.

Authors: Syed Abbas Ali; Victoria Shi; Irina Maric; Michael Wang; David F Stroncek; Jeremy J Rose; Jennifer N Brudno; Maryalice Stetler-Stevenson; Steven A Feldman; Brenna G Hansen; Vicki S Fellowes; Frances T Hakim; Ronald E Gress; James N Kochenderfer
Journal: Blood Date: 2016-07-13 Impact factor: 22.113

5. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.

Authors: Jennifer N Brudno; Irina Maric; Steven D Hartman; Jeremy J Rose; Michael Wang; Norris Lam; Maryalice Stetler-Stevenson; Dalia Salem; Constance Yuan; Steven Pavletic; Jennifer A Kanakry; Syed Abbas Ali; Lekha Mikkilineni; Steven A Feldman; David F Stroncek; Brenna G Hansen; Judith Lawrence; Rashmika Patel; Frances Hakim; Ronald E Gress; James N Kochenderfer
Journal: J Clin Oncol Date: 2018-05-29 Impact factor: 44.544

6. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

Authors: Edward A Stadtmauer; Dan T Vogl; Eline Luning Prak; Jean Boyer; Nicole A Aqui; Aaron P Rapoport; Kenyetta R McDonald; Xiaoling Hou; Heather Murphy; Rita Bhagat; Patricia A Mangan; Anne Chew; Elizabeth A Veloso; Bruce L Levine; Robert H Vonderheide; Abbas F Jawad; Carl H June; Kathleen E Sullivan
Journal: Blood Date: 2010-09-23 Impact factor: 22.113

7. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Authors: Aaron P Rapoport; Nicole A Aqui; Edward A Stadtmauer; Dan T Vogl; Yin Yan Xu; Michael Kalos; Ling Cai; Hong-Bin Fang; Brendan M Weiss; Ashraf Badros; Saul Yanovich; Gorgun Akpek; Patricia Tsao; Alan Cross; Dean Mann; Sunita Philip; Naseem Kerr; Andrea Brennan; Zhaohui Zheng; Kathleen Ruehle; Todd Milliron; Scott E Strome; Andres M Salazar; Bruce L Levine; Carl H June
Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531

8. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

Authors: Aaron P Rapoport; Edward A Stadtmauer; Nicole Aqui; Dan Vogl; Anne Chew; Hong-Bin Fang; Stephen Janofsky; Kelly Yager; Elizabeth Veloso; Zhaohui Zheng; Todd Milliron; Sandra Westphal; Julio Cotte; Hong Huynh; Andrea Cannon; Saul Yanovich; Gorgun Akpek; Ming Tan; Kristen Virts; Kathleen Ruehle; Carolynn Harris; Sunita Philip; Robert H Vonderheide; Bruce L Levine; Carl H June
Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531

9. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors: Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal: Nat Med Date: 2018-04-30 Impact factor: 53.440

10. Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors: Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal: J Exp Med Date: 2003-11-24 Impact factor: 14.307

38 in total

Review 1. Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors: Rebecca C Larson; Marcela V Maus
Journal: Nat Rev Cancer Date: 2021-01-22 Impact factor: 60.716

Review 2. Future of CAR T cells in multiple myeloma.

Authors: Kitsada Wudhikarn; Sham Mailankody; Eric L Smith
Journal: Hematology Am Soc Hematol Educ Program Date: 2020-12-04

Review 3. CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Authors: Jian-Qing Mi; Jie Xu; Jianfeng Zhou; Weili Zhao; Zhu Chen; J Joseph Melenhorst; Saijuan Chen
Journal: Front Med Date: 2021-12-18 Impact factor: 4.592

4. Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.

Authors: Colby R Maldini; Andrea C Love; Kevin W Tosh; Leo Li-Ying Chan; Kevin Gayout; Tim Smith; James L Riley
Journal: J Immunol Methods Date: 2020-08-01 Impact factor: 2.303

5. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy.

Authors: Pei-Hsuan Chen; Mikel Lipschitz; Jason L Weirather; Caron Jacobson; Philippe Armand; Kyle Wright; F Stephen Hodi; Zachary J Roberts; Stuart A Sievers; John Rossi; Adrian Bot; William Go; Scott J Rodig
Journal: JCI Insight Date: 2020-06-18

Review 6. Immunotherapy of multiple myeloma.

Authors: Simone A Minnie; Geoffrey R Hill
Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808

Review 10. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.

Authors: Muhammad Sadeqi Nezhad; Meghdad Abdollahpour-Alitappeh; Behzad Rezaei; Mahboubeh Yazdanifar; Alexander Marcus Seifalian
Journal: Pharm Res Date: 2021-06-10 Impact factor: 4.200